ClinicalTrials.gg
RecruitingNCT05592132DOREVIUpdated Sep 11, 2026

Use of Virtual Reality in Pain Management in Pediatric Oncology

An interventional study of Virtual reality headset in Pediatric Tumor, sponsored by Centre Hospitalier Universitaire de la Réunion. Recruiting at 1 site in Reunion. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Centre Hospitalier Universitaire de la Réunion · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Study summary

DOREVI is a monocentric randomized controlled study that will evaluate the efficacy of virtual reality helmets for pain prevention during invasive care on 78 oncologic pediatric patients. Two groups of children (between 6 and 11 and between 12 and 18 years old) will be randomized to use helmet plus standard care or standard care alone during invasive procedures (central venous catheter puncture, lumbar puncture, or bone marrow aspiration). The pain intensity will be evaluated using a visual analogic scale during three invasive procedures, and results will be compared between the patients with or without virtual reality.

02

Conditions studied

  • Pediatric Tumor

Browse trials for

03

In context

Neoplasms

10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 74 is above the median of 60 across 7,703 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Centre Hospitalier Universitaire de la Réunion is the lead sponsor of 141 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patient who tolerates the virtual reality headset
  • patient followed in pediatric oncology
  • patient with a diagnosis of benign tumor or cancer
  • patient who needs to have painful medical procedure during their treatment
  • patient whose parents have signed the
  • patient affiliated with social security or equivalent

Exclusion criteria

Exclusion Criteria:

  • patient with visual or hearing impairement
  • patient with epilepsy or other neurological disease
  • patient with psychiatric disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    Intervention

    Patients randomized in this arm will have the virtual reality headset associated to the standard care

    Other: Virtual reality headset

  • No intervention
    Standard care

    patients randomized in this arm will have standard care.

Interventions

  • OtherVirtual reality headset

    Each patient in this treatment group will use a virtual reality headset during 3 procedures. During each procedure, the pain level will be assessed and compared with the assessed group.

06

What researchers measure

Primary outcomes

  1. Self pain evaluation

    Pain will be assessed by the analogic visual scale (minimal score = 0 (no pain) , maximal score = 10 (maximal pain))

    Time frame: before blood sampling on catheter with implantable chamber

07

Study locations

1 of 1 sites recruiting
  • CHU de La Réunion
    Saint-Denis, 97400, Reunion
    Recruiting
    • Yves REGUERRE, MD · Contact
    • Yves REGUERRE, MD · Principal investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05592132
Responsible party
Sponsor
First posted
Oct 24, 2022
Start date
Jan 17, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 11, 2026

Study contacts

Yves REGUERRE
Contact
yves.reguerre@chu-reunion.fr
+262262905676
Emilie TECHER
Contact
emilie.techer@chu-reunion.fr
+262262906289
Yves REGUERRE
principal investigator · CHU de La Réunion

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion